Novo Nordisk announced plans to launch its first “smart” insulin pens next year.
In addition, to integrate it smartpens with broader digital health solutions, Novo Nordisk has signed new partnership agreements with leading diabetes technology companies, Dexcom, Glooko and Roche.
Building upon its existing work with IBM Watson Health® and Glooko, Novo Nordisk aims to integrate insulin dosing data from connected pen devices with its partners’ open ecosystems and diabetes management solutions, such as data from continuous glucose monitoring (CGM) systems and blood glucose meters (BGM).
“Our non-exclusive partnership strategy allows us to integrate with the various digital platforms that people are already using to help manage their diabetes,” said Camilla Sylvest, executive vice president of commercial strategy & corporate affairs at Novo Nordisk in a statement.
The launch of Novo Nordisk’s first connected insulin pens, NovoPen® 6 and NovoPen Echo® Plus, will commence in the first quarter of 2019 and roll out to over 50 countries in the coming years.
NovoPen® 6 and NovoPen Echo®Plus will eventually be phased in to replace NovoPen® 5 and NovoPen Echo®in countries where those devices are currently available.
Novo Nordisk will also integrate insulin dosing data with Dexcom CGM data in the coming years.
Beyond launching connected durable devices, Novo Nordisk expects to deliver connectivity for its disposable, pre-filled injection pens later in 2019.
In the longer term, Novo Nordisk aims to increase the availability of connected pens and offer solutions for personalized treatment guidance.
Image Courtesy: The NovoPen Echo.® Novo Nordisk.
- “Novo Nordisk plans the first global launch of connected insulin pens and announces key digital health partnerships.” Oct. 1, 2008. Retrieved: